RBM10 and neoplasm: Consistent with these clinical data, other investigators observed early clinical progression associated with decreased sensitivity to EGFR TKI therapy in a patient with EGFRL858R lung cancer whose tumor also harbored a clonal co-occurring truncating RBM10 mutation (13).